All News
Emergency Department Visits by Rheumatoid Patients
A Canadian population study shows that rheumatoid arthritis (RA) patients have 30% higher emergency department (ED) visit rates for Ambulatory Care Sensitive Conditions (ACSCs) compared to age- and sex-matched population controls.
Smartphones and Rheumatoid Flares
FORWARD Databank of Rheumatoid arthritis (RA) patients reveals that smartphone data can predict flares using PROs.
Nurse Practitioner Independence
A JAMA Viewpoint article reports on a March 2025 Nurse Practitioner (NP) Entrepreneurship Summit in Boston in March 2025 identifying barriers and opportunities to NP-owned medical practices.
Read Article
Nurse Practitioner Independence
A JAMA Viewpoint article reports on a March 2025 Nurse Practitioner (NP) Entrepreneurship Summit in Boston in March 2025 identifying barriers and opportunities to NP-owned medical practices.
https://t.co/rkzLwhnNYh https://t.co/bxJWptPQK9
Links:
Dr. John Cush RheumNow ( View Tweet)
2024 Cardiology Income Survey - CV APP salary has incr 15% from 2019 -23, median=$123K - 50% of APP programs lead by an APP >90% work in outpt. clinics - 2/3 of prgs deploy APPs lipid & prevention management - 2 APPs for every 3 cardiologists https://t.co/gtdm5qN1qD https://t.co/cx2JUcw4U3
Links:
Dr. John Cush RheumNow ( View Tweet)
German psoriasis registry PsoBest reports on 595 Rx w/ apremilast (417 APR monotherapy). Compared to Ptx Rx w/ other DMARDs/biologic drugs, APR pts higher age, more comorbidities. Nonserious AEs: ineffectiveness (14%), diarrhea (9%), nausea (7%), HA (6%). https://t.co/TviJmM7Fr9 https://t.co/tY89oHgUgV
Dr. John Cush RheumNow ( View Tweet)
Evaluation of pts w/ muscle weakness and elevated muscle enzymes https://t.co/1Yn3OXXEH6 https://t.co/qsTr4U1xV7
Dr. John Cush RheumNow ( View Tweet)
Diffuse Alveolar Hemorrhage in Rheumatic Disease
A retrospective, cross-sectional, single-center study of adult rheumatic disease patients with diffuse alveolar hemorrhage (DAH), demonstrates a high proportion have coexistent pulmonary infection and significant mortality risk. https://t.co/K1fLo5iHpd
Dr. John Cush RheumNow ( View Tweet)
Drugs that may cause toxic myopathy, presenting as muscle dysfunction w/ weakness and elevated muscle enzymes and possibly confused w/ idiopathic inflammatory myopathies (IIM) - full read review of mimickers of myositis. https://t.co/3wdLvkxcAX https://t.co/OqLjv45HXH
Dr. John Cush RheumNow ( View Tweet)
Subcutaneous Anifrolumab in SLE
Manzi et al. have published the results of the TULIP-SC trial that showed that weekly subcutaneous (SC) anifrolumab, when given to severe SLE patients, had comparable efficacy and safety to the approved intravenous (IV) anifrolumab. https://t.co/ruZM3Qftxb
Dr. John Cush RheumNow ( View Tweet)
Rheum Survey> 40 yoF RA pt on Prednisone 5 mg/d is at increased risk for ?
Dr. John Cush RheumNow ( View Tweet)
RheumNow Live is 3 weeks away, and we can't wait to see you there!
Why Attend In Person?
✔ Engage directly with faculty during live Q&A
✔ Network with peers who influence and lead in rheumatology
✔ Experience the energy, pace, and collaboration that can’t be replicated https://t.co/Do8srChyXW
Dr. John Cush RheumNow ( View Tweet)
The 2025 Rheumatology Year in Review
The year 2025 presented numerous advances in rheumatology and related inflammatory and autoimmune disorders, ranging from several new groundbreaking FDA approvals/indications, drug developments, game-changing guidelines, and practices that https://t.co/gjNesm0AWO
Dr. John Cush RheumNow ( View Tweet)
ANAs and Autoantibodies
https://t.co/PTdXPMCqjP https://t.co/Pbtgaod3uW
Links:
Dr. John Cush RheumNow ( View Tweet)
FDA & Administration are deregulating artificial intelligence & promote widespread use, includes use of wearables & other AI-enabled devices. Commissioner Marty Makary updated two guidance docs defining use general wellness devices, clinical decision support software https://t.co/KnkYqCiroa
Dr. John Cush RheumNow ( View Tweet)
QD Clinic: Sjogren's Beyond the Dryness
Caitlin Hill, FNP, and David Maniscalco, MD, Santa Rosa, CA present this QD Clinic: Sjogren's - Beyond the Dryness.
https://t.co/2U4Q2aRFec https://t.co/AGq36PT9iZ
Dr. John Cush RheumNow ( View Tweet)
Advanced Practitioner Biologic Prescriptions for Psoriasis
Advanced practice clinicians (APCs; nurse practitioners and physician assistants) deliver a large share of US dermatologic care, accounting for 37% of clinicians and 27% of dermatology visits by 2020. A current JAMA https://t.co/3NtntmpSPV
Dr. John Cush RheumNow ( View Tweet)
Spread of Psoriatic Disease from Skin to Joints
Approximately 20-30 % of all people who suffer from psoriasis also develop painful inflammation in their joints over time. If left untreated, PsA can lead to permanent damage to bones and joints. Why the disease progresses was https://t.co/UbGHFASKvc
Dr. John Cush RheumNow ( View Tweet)
Retrospective study of recombinant zoster vaccine Rheumatic (RMD) pts on DMARDs (32% JAKi) (114) vs 65 normals. HZoster reactivation: no controls vs 1in RMD. 1 Dz flare requiried steroids. Minor AE (ISR, HA, myalgia) seen in 17.5% & 21.5% w/ 1st & 2nd dose. RZV is safe in RMD https://t.co/Mu3OyA4EOD
Dr. John Cush RheumNow ( View Tweet)
Metanalysis of 21 clinical trials, 2,100 adults, shows cannabis-based medicines (vs placebo) over 2-26 weeks are not effective in treating chronic neuropathy nerve pain, regardless if given as THC of CBD. https://t.co/ZOJrcMGZkr https://t.co/nqCWoFmaWp
Links:
Dr. John Cush RheumNow ( View Tweet)
